Cart
sales@molnova.com
WHI-P154
CAS No. 211555-04-3
WHI-P154( JAK3 Inhibitor II | Janus-Associated Kinase 3 Inhibitor II )
Catalog No. M13364 CAS No. 211555-04-3
WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 55 | In Stock |
|
| 2MG | 33 | In Stock |
|
| 5MG | 53 | In Stock |
|
| 10MG | 84 | In Stock |
|
| 25MG | 176 | In Stock |
|
| 50MG | 325 | In Stock |
|
| 100MG | 527 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWHI-P154
-
NoteResearch use only, not for human use.
-
Brief DescriptionWHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
-
DescriptionWHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
-
In Vitro——
-
In Vivo——
-
SynonymsJAK3 Inhibitor II | Janus-Associated Kinase 3 Inhibitor II
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR| JAK3| Src| VEGFR
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number211555-04-3
-
Formula Weight376.2
-
Molecular FormulaC16H14BrN3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 75 mg/mL (199.36 mM)
-
SMILESOC1=CC=C(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)C=C1Br
-
Chemical Name2-Bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.O'Donoghue ML, et al. J Thromb Thrombolysis. 2012 Jul;34(1):36-43.
molnova catalog
related products
-
Erlotinib hydrochlor...
Erlotinib (CP-358774;OSI-774;NSC 718781) is a potent, selective inhibitor of EGFR with IC50 of 2 nM.
-
Befotertinib
Befotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
-
Olmutinib (b)
Olmutinib (HM61713, BI-1482694) is a pontent and T790M-specific third-generation EGFR inhibitor for treatment of NSCLC.
